This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Contract Research Organizations (CROs) Market To 2018 - Public-Private Partnerships To Strengthen Research Capacities And Advance Clinical Development Programs

NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Contract Research Organizations (CROs) Market to 2018 - Public-Private Partnerships to Strengthen Research Capacities and Advance Clinical Development Programs

http://www.reportlinker.com/p0845626/Contract-Research-Organizations-CROs-Market-to-2018---Public-Private-Partnerships-to-Strengthen-Research-Capacities-and-Advance-Clinical-Development-Programs.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

Contract Research Organizations (CROs) Market to 2018 - Public-Private Partnerships to Strengthen Research Capacities and Advance Clinical Development Programs

Summary

GBI Research, the leading business intelligence provider, has released its latest report, "Contract Research Organizations (CROs) Market to 2018 - Public-Private Partnerships to Strengthen Research Capacities and Advance Clinical Development Programs", which provides key data, information and analysis of CRO industry. The report provides a comprehensive insight into the size of the CRO market, and includes forecasts, key reasons for outsourcing, technology developments affecting CRO's, public private partnerships, profiles of top CROs, drivers and restraints and deals analysis.

This report is built using data and information sourced from proprietary databases, primary and secondary research and uses in-house analysis from GBI Research's team of industry experts.

CRO industry market revenues were estimated to total $21.4 billion in 2010. In 2009 the revenues recorded were $19.1 billion. From 2009 to 2010 the industry grew at the rate of 12% which is considered to be very healthy in comparison to the other R&D industry growth. According to clinicaltrials.gov by November 2011, 43.9% of the clinical trials were carried out in the US. 22.9% of the trials were carried out in Europe. 11.6% of the trials were carried out in Asia and the rest of the clinical trials were carried out in Canada, Mexico, Australia, Middle East and Africa approximating 21.4% of the total clinical trials. GBI research estimates that the global R&D outsourcing market in 2010 was 25.3% of the total pharmaceutical R&D expenditure. The expenditure is estimated to increase at the rate of 5% annually and is expected to reach 37.1% of the total R&D expenditure by 2018. All the companies are looking to cut down the time for launch of drugs along with a reduction in the expenditure on R&D.

Scope

- Detailed overview of the CRO industry.

- Annualized market data and forecasts for the CRO market.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,748.50 -179.70 -1.00%
S&P 500 2,070.14 -19.32 -0.92%
NASDAQ 4,892.6980 -46.6290 -0.94%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs